Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
Industry veteran with decades of experience in company formation, scientific research, and drug development to join executive leadership team to accelerate pipeline potential
BOSTON and LONDON, Oct. 05, 2021 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that David Grainger, PhD, has been appointed to the newly-created role of Chief Innovation Officer. Dr. Grainger will be a member of the Company’s executive leadership team and will be responsible for the overall management of the scientific and research activities. Dr. Grainger will work collaboratively with the scientific leadership team in each of the Centessa companies and will provide guidance and insight to the scientific approaches and teams. His responsibilities will also include discovery efforts, playing a pivotal role in defining how therapeutic candidates will be selected and validated for development.
